Clinical Trials Logo

Clinical Trial Summary

Thrombo-embolic venous diseases are represented by deep venous thrombosis and/or pulmonary embolism. In some patients with repeated thrombosis or occurrence of thrombosis in unusual sites, the etiological workup remains negative, which represents a problem for the management of the anticoagulant treatments. Recently, two factors have been identified as important in the physiopathology of hemostasis and coagulation: the presence of clonal hematopoiesis of indetermined potential (CHIP) and the formation of neutrophil extracellular traps (NETs). In this study, these two factors will be studied in patients with repeated venous thrombosis or thrombosis occurring in unusual site.


Clinical Trial Description

It has recently been shown that some patients clonal have mutations at a low level in hematopoietic cells (this phenomenon is named clonal hematopoiesis of indetermined potential (CHIP)) and that the presence of a clonal hematopoiesis is associated with an increased cardiovascular risk. However, few data exist about the implication of CHIP in venous thrombosis. Neutrophils extracellular traps are involved in the activation of hemostasis and coagulation. Murine models have highlighted the crucial role of NETs in the physiopathology of venous thrombosis. In patients, studies have demonstrated that NETs markers were present in arteries lesions as coronary plaques. However, few studies have analyzed the NETosis in the setting of venous thrombosis. The study hypothesis is that patients with venous thrombosis may have an increased prevalence of CHIP and/or an increased NETosis formation, which may represent a predisposition for the occurrence of venous thrombosis. We also speculate that patients with CHIP may have an increased NETosis, due to the presence of activating clonal mutations in neutrophils. Patients included will be : younger than 50-years-old with repeated thrombosis or thrombosis of unusual sites (cerebral venous thrombosis, splanchnic thrombosis) with a negative etiological workup and notably the absence of constitutional or acquired venous thrombosis risk factors. In this population, we will analyze the prevalence of CHIP and the NETosis via the study of 4 different NETosis plasmatic markers. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05711173
Study type Interventional
Source University Hospital, Bordeaux
Contact Alexandre GUY
Phone 0557656478
Email alexandre.guy@chu-bordeaux.fr
Status Recruiting
Phase N/A
Start date March 3, 2023
Completion date March 2025

See also
  Status Clinical Trial Phase
Withdrawn NCT03613402 - BRAVO - Betrixaban Registry Using Real Time Observations in Acute Medical Illness to Assess Venous Thrombosis and Bleeding Outcomes
Recruiting NCT05409976 - The GORE® VIAFORT Vascular Stent IVC Study N/A
Completed NCT03015025 - Pharmacogenetic Dosage Algorithm for Acenocoumarol N/A
Completed NCT03911661 - Fearon Algorithm in Warfarin Patient Self-Management N/A
Recruiting NCT05449808 - Evaluation of Thromboprophylaxis Appropriateness in Hospitalized Medical Patients
Withdrawn NCT05246943 - The Correlation of a D-dimer Testing Protocol With Venous Thromboembolism in Surgical Colorectal Patients
Recruiting NCT01339611 - Education Program for Patients Receiving Oral Anticoagulation N/A
Completed NCT04367831 - Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19 Phase 4
Completed NCT04824118 - Clotting Parameters After Medical Abortion
Withdrawn NCT01810237 - Validation of a Novel Dabigatran Based Peri-Operative Bridging Anticoagulation Protocol for Patients on Chronic Warfarin Therapy N/A
Recruiting NCT05489588 - The GORE® VIAFORT Vascular Stent Iliofemoral Study N/A
Completed NCT05087108 - Evaluation of the OsciPulse Rapid Cycling Compression Device Effects on Venous Blood Flow Early Phase 1
Terminated NCT04128956 - Aspirin® Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis in Patients With PTS Phase 2
Completed NCT04439383 - Risk Stratification for Venous Thromboembolism in Hospitalized Medical Patients
Not yet recruiting NCT06452342 - TRanEXamic Acid to Decrease Heavy Menstrual Bleeding in Individuals Anticoagulated for Venous Thromboembolism Pilot Study Phase 4
Recruiting NCT06087952 - Leiden Thrombosis Recurrence Risk Prevention N/A
Completed NCT05515120 - Rivaroxaban Plus Aspirin to Manage Recurrent Venous Thromboembolic Events Phase 2/Phase 3
Completed NCT03611894 - Comparison of the Radiological Pattern Between the Cerebral Stroke of Arterial and Venous Origin
Completed NCT03835780 - The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a United Kingdom (UK) Matched Cohort Study
Recruiting NCT05729464 - Risk Factors and Prediction Model of Cancer-associated Venous Thromboembolism